Ullem Scott B.
SEC Form 4 insider trading activity
Ullem Scott B. has filed 14 SEC Form 4 filings (25 transaction rows) across 2 companies, including ILMN, EW, with disclosures dating back to 2025. 13 of those filings fall inside the rolling window. Most recent filing: Oct 2, 2026.
On the most recent filing, Ullem Scott B. is listed as CVP, Chief Financial Officer at Edwards Lifesciences Corp. Inside the rolling window, Ullem Scott B. reported no open-market purchases and 4 open-market sales totaling $3.9M in EW. The largest disclosed transaction in the window is a sale of 13,000 EW shares on Mar 11, 2026, worth $1.1M.
Companies traded
Other insiders at ILMN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.9M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Ullem Scott B. made?
Ullem Scott B. has filed 14 SEC Form 4 filings (25 transaction rows) across 2 companies, including ILMN, EW since 2025.
Which companies does Ullem Scott B. trade?
Ullem Scott B. has filed SEC Form 4 disclosures for 2 companies, including ILMN, EW.
When was Ullem Scott B.'s most recent SEC Form 4 filing?
Ullem Scott B.'s most recent SEC Form 4 filing on Tracefour is dated Oct 2, 2026.
What is Ullem Scott B.'s total buy and sell value in the current window?
Inside the rolling retention window, Ullem Scott B. bought $0 and sold $3.9M based on SEC Form 4 filings.
What was Ullem Scott B.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 13,000 EW shares on 2026-03-11, worth $1.1M, per SEC Form 4 filings.